Table 1.
Compounds | PS added to cells along with SARS-CoV-2 (IC50 μg/mL) | PS added to cells 3.5 h post infection with SARS-CoV-2 (IC50 μg/mL) | CC50 μg/mL |
---|---|---|---|
MB | 0.22 ± 0.07 | 0.66 ± 0.23 | 100 ± 24.0 |
Radachlorin | 0.33 ± 0.09 | 2.0 ± 0.60 | 50 ± 15.0 |
T-705 and T-1105 | ≥ 60 | NT | > 250* |
Note: Data are the mean ± SEM of 3 independent tests (3 replicates for one test per concentration; the ranges of concentrations tested were 150−0.06 μg/mL for MB and Radachlorin and 60−0.02 μg/mL for T-705 and T-1105). Antiviral activity is expressed as the IC50, defined as the compound concentration producing 50 % inhibition of virus replication, as estimated by microscopic scoring of the CPE and by measuring cell viability in the formazan-based MTT assay. Cytotoxicity is expressed as the CC50, the compound concentration producing 50 % cytotoxic effect estimated by the MTT cell viability assay.
The T-705 and T-1105 compounds were kindly provided by Prof. Tikhonov A.Y. (N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the SB RAS) as potential inhibitors for viral RNA-dependent RNA polymerase of influenza virus. *the CC50 value [17]. NT - not tested.